Pfizer and BioNTech are confident they can have a vaccine against the novel coronavirus ready for regulatory approval by the middle of October, BioNTech CEO and co-founder Ugur Sahin said.
"It has an excellent profile and I consider this vaccine ... near perfect, and which has a near perfect profile," Sahin said in an interview, reports the CNN.
He added that the company's "understanding of the mode of action, in combination with the safety data coming in from the running trial" meant that they have "a lot of confidence" in it.
"Yes, we believe that we have a safe product and we believe that we will be able to show efficacy," he said.
Sahin said that he believes that approval for emergency use will be granted quickly by regulatory authorities.
US drug giant Pfizer and German firm BioNTech say they plan to provide 100 million doses of their vaccine candidate, BNT162, by the end of the year, and up to 1.3 billion doses in 2021.